Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. on August 9, 2018. The report discloses a change in the Company's independent registered public accountants. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of the external auditor.
Material Changes
- Accountant Change: The Company engaged Marcum LLP as its new independent registered public accountants effective August 9, 2018.
- Reason for Change: The prior accountant, GBH CPAs, PC, resigned due to the combination of its practice with Marcum, effective July 1, 2018.
- Approval: The engagement of Marcum LLP was approved by the Audit Committee of the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of new risks. Regarding the transition, the Company disclosed the following:
- GBH CPAs' reports for fiscal years 2016 and 2017 contained no adverse opinions, disclaimers, or qualifications.
- There were no disagreements with GBH CPAs regarding accounting principles, practices, or audit scope during the relevant periods.
- The Company did not consult with Marcum LLP on any accounting matters prior to the engagement.
Investor Verification Checklist
- Verify the effective date of the auditor transition (July 1, 2018, for practice combination; August 9, 2018, for formal engagement).
- Confirm the absence of any disagreements or "reportable events" with the former auditor, GBH CPAs, PC.
- Review the letter from GBH CPAs, PC (Exhibit 16.1) to ensure they concur with the Company's disclosures.
- Note that this filing does not provide updated financial results; refer to the most recent 10-Q or 10-K for financial metrics.